Business Wire

Sierra Wireless Launches Innovative Smart SIM with Superior Global IoT Connectivity Service

Del

Sierra Wireless (NASDAQ:SWIR) (TSX:SW) today announced its Smart SIM technology and connectivity service that provide customers with superior coverage and service quality to accelerate the deployment of global IoT applications. With the addition of its global Smart SIM offering, Sierra Wireless delivers the most comprehensive, fully integrated device-to-cloud solution, including hardware, managed connectivity, and cloud services for multi-operator, multi-regional IoT deployments.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160215005731/en/

Sierra Wireless Smart SIM and connectivity service provide superior coverage and service quality to  ...

Sierra Wireless Smart SIM and connectivity service provide superior coverage and service quality to accelerate the deployment of global IoT applications. (Photo: Business Wire)

“Our Smart SIM technology allows us to provide our customers with a connectivity service designed for the coverage and quality of service that their IoT use cases require,” said Emmanuel Walckenaer, Senior Vice President, Cloud and Connectivity Services at Sierra Wireless. “When combined with our IoT Acceleration Platform, this unique, fully integrated device-to-cloud service accelerates our customers’ time-to-market.”

There are three unique benefits to the Sierra Wireless Smart SIM:

  • Extensive coverage – the Smart SIM automatically selects networks based on the best service available in any given location. It comes with multiple operator profiles already installed, effectively combining several MNO roaming SIMs into one physical Smart SIM. The on-board patented applet then intelligently selects the best available regional network operator at any given time. This results in better coverage and service up-time.
  • Smart network connectivity and superior Quality of Service (QoS) – Sierra Wireless’ fully redundant core network is designed and built for IoT connectivity and applications. The multi-operator Smart SIM selects the best available cellular network in any given location, ensuring the best possible data connection at all times. In the event a device loses network signal, whether in-transit or otherwise, the Smart SIM will detect this and re-establish the connection with another network automatically.
  • Cost-effective simplicity – with a single Smart SIM and unified IoT Acceleration platform, Sierra Wireless vastly simplifies global IoT deployments, saving customers the time and expense of having to arrange multiple service agreements, SIMs and platforms, and the management of disparate vendors (see white paper for more information).

“The QoS capability of Sierra Wireless’ innovative Smart SIM technology was a key factor in our vendor selection process because we needed to maximize coverage across multiple network operators,” said Chris Gnanakone, Founder and Co-CEO for Nube, an energy management company based in Latin America. “It was important for us to choose a partner that could eliminate much of the technical risk in our solution. We were able to get to market faster because Sierra Wireless’ hardware is pre-integrated with the cloud platform.”

“In the payments industry it is crucial that our terminals are connected at all times, allowing our customers to transact business,” said Daniel Nordholm, CTO for Bambora, a global payments company headquartered in Sweden. “The broader coverage benefits of the Sierra Wireless Smart SIM ensure we can deliver service to our customers at all times. We were also looking for a single SIM solution to serve all of our terminals regardless of geography in order to drive down the complexity and cost of deploying and supporting our global customers."

Sierra Wireless has more than 700,000 SIM subscribers globally that count on its connectivity offering to power their IoT deployments. Customers manage and automate all aspects of the Sierra Wireless Smart SIM using the IoT Acceleration Platform, providing a simple way to integrate SIM logistics into their connected product or service. The IoT Acceleration Platform is unique in the industry in that it can also manage third-party network operator SIMs, providing customers a single unified connectivity management platform for all deployed SIMs.

The addition of the Smart SIM and Connectivity service to the broader Sierra Wireless portfolio now provides customers with all of the service infrastructure they require to create, deploy and manage their IoT applications. By integrating connectivity management, operations management and application enablement services into one unique platform, customers spend less time integrating multiple platforms, allowing them to accelerate their deployment of connected products and services.

Sierra Wireless’ connectivity service operates on 2G and 3G today, and LTE will be available in Q2 2016 on a worldwide basis. The Smart SIM is already LTE-ready and available today. For more information about Smart SIM, please visit http://www.sierrawireless.com/SIM.

Sierra Wireless will showcase Smart SIM connectivity at Mobile World Congress, February 22-25, in Barcelona. Visit the Sierra Wireless stand in Hall 3, Stand 3A11 of the Innovation City.

Emmanuel Walckenaer, Senior Vice President, Cloud and Connectivity Services, will present at Mobile World Congress on a panel discussing the Reinvention of the MVNO, on Wednesday, February 24, at 11:00am: http://bit.ly/1RQtNbh. The panel is sponsored by the GSMA and Emmanuel will talk about new opportunities for global IoT connectivity services.

For more detailed information about the Sierra Wireless Smart SIM, please attend the webinar, The Emergence of IoT Specific SIMs and Networks, on March 1, 2016, at 11:00 AM EST / 5:00 PM CET. Dan Shey, Managing Director and VP - B2B, ABI Research, Cyril Hullin, VP Product Strategy & Marketing and Scott Waldrum, Director of Marketing for Cloud and Connectivity Services, Sierra Wireless will present and host a Q&A session. Register at: http://bit.ly/1RHoOci. Download the white paper, Moving Beyond Consumer SIMs for IoT, at: http://bit.ly/1okGPSo.

Visit the Sierra Wireless website for more information about the Sierra Wireless IoT Acceleration Platform.

To contact the Sierra Wireless Sales Desk, call +1 877-687-7795 or visit http://www.sierrawireless.com/sales.

Note to editors:

To view and download images of Sierra Wireless products, please visit http://www.sierrawireless.com/newsroom/productimages.aspx.

About Sierra Wireless

Sierra Wireless (NASDAQ: SWIR) (TSX: SW) is building the Internet of Things with intelligent wireless solutions that empower organizations to innovate in the connected world. We offer the industry’s most comprehensive portfolio of 2G, 3G and 4G embedded modules and gateways, seamlessly integrated with our secure cloud and connectivity services. OEMs and enterprises worldwide trust our innovative solutions to get their connected products and services to market faster. Sierra Wireless has more than 1,000 employees globally and operates R&D centers in North America, Europe and Asia. For more information, visit www.sierrawireless.com.

Sierra Wireless is a registered trademark of Sierra Wireless. Other product or service names mentioned herein may be the trademarks of their respective owners.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply conditions, channel and end customer demand conditions, revenues, gross margins, operating expenses, profits, and other expectations, intentions, and plans contained in this press release that are not historical fact. Our expectations regarding future revenues and earnings depend in part upon our ability to successfully develop, manufacture, and supply products that we do not produce today and that meet defined specifications. When used in this press release, the words "plan", "expect", "believe", and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the wireless data communications market. In light of the many risks and uncertainties surrounding the wireless data communications market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.

Contact information

Sierra Wireless - Europe & UK
Mette Hautemaniere, +33 1 46 29 94 17
MHA@sierrawireless.com
or
Sierra Wireless – North America
Kim Homeniuk, +1 604 233 8028
khomeniuk@sierrawireless.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom